Johnson & Johnson (JNJ) Releases Earnings Results, Beats Expectations By $0.04 EPS

Share on StockTwits

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday. The company reported $2.10 EPS for the quarter, topping analysts’ consensus estimates of $2.06 by $0.04, MarketWatch Earnings reports. Johnson & Johnson had a return on equity of 35.63% and a net margin of 18.75%. The firm had revenue of $20.02 billion for the quarter, compared to the consensus estimate of $19.55 billion. During the same quarter in the prior year, the business earned $2.06 earnings per share. The company’s revenue was up .1% compared to the same quarter last year. Johnson & Johnson updated its FY 2019 guidance to $8.53-8.63 EPS and its FY19 guidance to $8.53-8.63 EPS.

Shares of JNJ stock opened at $138.02 on Wednesday. The company has a market cap of $370.29 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 2.21 and a beta of 0.68. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 12-month low of $118.62 and a 12-month high of $148.99.

JNJ has been the topic of a number of recent research reports. Zacks Investment Research downgraded Johnson & Johnson from a “hold” rating to a “sell” rating in a research note on Wednesday, January 16th. Citigroup lowered their target price on Johnson & Johnson from $148.00 to $139.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 2nd. Wells Fargo & Co restated an “outperform” rating and issued a $152.00 target price (down previously from $162.00) on shares of Johnson & Johnson in a research note on Monday, January 14th. Barclays restated an “equal weight” rating and issued a $135.00 target price (down previously from $137.00) on shares of Johnson & Johnson in a research note on Wednesday, January 23rd. Finally, Morgan Stanley set a $140.00 target price on Johnson & Johnson and gave the stock a “hold” rating in a research note on Thursday, December 20th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $143.58.

Hedge funds have recently modified their holdings of the business. Fundsmith Equity Fund L.P. bought a new stake in shares of Johnson & Johnson during the second quarter worth $552,762,000. Chicago Partners Investment Group LLC grew its position in Johnson & Johnson by 3.7% in the second quarter. Chicago Partners Investment Group LLC now owns 12,011 shares of the company’s stock valued at $1,457,000 after purchasing an additional 431 shares in the last quarter. Ashburton Jersey Ltd grew its position in Johnson & Johnson by 6.0% in the second quarter. Ashburton Jersey Ltd now owns 145,725 shares of the company’s stock valued at $17,682,000 after purchasing an additional 8,196 shares in the last quarter. Exane Asset Management bought a new position in Johnson & Johnson in the second quarter valued at $206,000. Finally, SP Asset Management bought a new position in Johnson & Johnson in the second quarter valued at $11,792,000. Institutional investors own 67.32% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece was first reported by Macon Daily and is owned by of Macon Daily. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://macondaily.com/2019/04/17/johnson-johnson-jnj-releases-earnings-results-beats-expectations-by-0-04-eps.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Quick Ratio

Earnings History for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.